EIC Accelerator

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

Blykalla is a Swedish company focused on the development and production of advanced small modular reactors (SMRs). Drawing on more than 25 years of research, its reactor concepts aim to provide reliable baseload energy to support a fossil-free energy transition. The company develops lead-cooled reactor designs, featuring cores configured to achieve criticality with enriched uranium oxide fuels, enabling clients to develop, license, and operate small lead-cooled reactors in Sweden. Blykalla emphasizes safety and modularity, offering scalable power solutions for diverse sites while reducing carbon emissions.

SemiQon is a Finnish startup spun out from VTT Technical Research Centre. It specializes in developing silicon-based quantum processors using novel semiconductor qubit technology, aiming to advance the scalability and sustainability of quantum computing.

Blykalla is a Swedish company focused on the development and production of advanced small modular reactors (SMRs). Drawing on more than 25 years of research, its reactor concepts aim to provide reliable baseload energy to support a fossil-free energy transition. The company develops lead-cooled reactor designs, featuring cores configured to achieve criticality with enriched uranium oxide fuels, enabling clients to develop, license, and operate small lead-cooled reactors in Sweden. Blykalla emphasizes safety and modularity, offering scalable power solutions for diverse sites while reducing carbon emissions.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Delta Cygni Labs develops POINTR, a remote video collaboration platform powered by augmented reality and a secure telecommunications protocol. The solution enables mission-critical field service across energy, machinery, and maritime industries, with deployments that support real-time video, artificial intelligence, drones, and the Internet of Things. The platform also includes projected augmented reality tools designed to assist astronauts in intra- and extravehicular activities, contributing to safer operations on Earth and in space. The company serves customers including KONE, Wärtsilä, Valmet, Schneider Electric, and Ford, and maintains offices and partnerships in Finland, Germany, Brazil, Russia, and Japan. Delta Cygni Labs focuses on secure, reliable communications for high-stakes environments and enables remote collaboration and data streaming for complex field tasks and space missions.

Delta Cygni Labs develops POINTR, a remote video collaboration platform powered by augmented reality and a secure telecommunications protocol. The solution enables mission-critical field service across energy, machinery, and maritime industries, with deployments that support real-time video, artificial intelligence, drones, and the Internet of Things. The platform also includes projected augmented reality tools designed to assist astronauts in intra- and extravehicular activities, contributing to safer operations on Earth and in space. The company serves customers including KONE, Wärtsilä, Valmet, Schneider Electric, and Ford, and maintains offices and partnerships in Finland, Germany, Brazil, Russia, and Japan. Delta Cygni Labs focuses on secure, reliable communications for high-stakes environments and enables remote collaboration and data streaming for complex field tasks and space missions.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

Qlucore is a prominent provider of advanced bioinformatics software designed for research and precision diagnostics in the life sciences. Founded in 2007 by researchers from Lund University in Sweden, the company aims to simplify the analysis of complex data generated in the fields of genetics and proteomics. Its flagship product, Qlucore Omics Explorer, is a user-friendly bioinformatics tool that enables researchers, technicians, and physicians to easily interpret and visualize large datasets. Additionally, Qlucore offers Qlucore Diagnostics, an AI-powered platform for multi-omics companion and precision diagnostics that integrates with various data-generating instruments. With a global presence, Qlucore serves customers in approximately 35 countries, including leading pharmaceutical companies, hospitals, and academic institutions.

Basemark specializes in developing augmented reality software for enhanced driver awareness and safety. It offers tools to avoid occlusion, prevent motion sickness, and support multiple in-vehicle displays, enabling automotive manufacturers to create practical AR applications.

IQM Quantum Computers, founded in 2018 and headquartered in Espoo, Finland, specializes in developing and manufacturing hardware systems for quantum computing. The company focuses on scalable hardware solutions utilizing superconducting technology to build quantum processors for universal quantum computers. By concentrating on practical applications, IQM aims to enhance quantum computing capabilities and address challenges faced by various industries and society. As a spin-out from Aalto University and the VTT Technical Research Centre of Finland, IQM has achieved significant advancements in areas such as thermal management, which are crucial for improving computational speed and information accuracy. The company's innovations position it as a leader in the global pursuit of large-scale quantum computing solutions. IQM also offers access to its hardware for research laboratories and supercomputing centers, helping businesses reduce error rates that currently limit computing performance.

Comptek Solutions is a Finnish developer specializing in advanced surface engineering for compound semiconductors. Its Kontrox quantum surface engineering process creates defect-free, crystalline surfaces on III-V materials, enabling higher-quality semiconductor devices used in CMOS manufacturing, radio frequency components, optoelectronics, power electronics, and concentrated photovoltaics. Founded in 2017 and based in Turku, the company also offers passivation technologies that mitigate aggressive oxidation, reducing atomic-level defects and improving device efficiency, reliability and manufacturability. Kontrox has demonstrated substantial performance gains in devices such as microLEDs, and the company provides customized services to fit diverse substrate and fabrication flows, helping clients produce more efficient, reliable, and affordable devices across optoelectronics, RF and power electronics markets.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.